BG Medicine (BGMD) Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test  
1/3/2013 8:59:05 AM

WALTHAM, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that the first automated version of the BGM Galectin-3® blood test has obtained a CE Mark, an important step in the company's commercial strategy.